These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20334535)

  • 1. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.
    Semba CP; Swearingen D; Smith VL; Newman MS; O'Neill CA; Burnier JP; Haughey DB; Gadek TR
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):99-104. PubMed ID: 20334535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.
    Paskowitz DM; Nguyen QD; Gehlbach P; Handa JT; Solomon S; Stark W; Shaikh O; Semba C; Gadek TR; Do DV
    Eye (Lond); 2012 Jul; 26(7):944-9. PubMed ID: 22538219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.
    Murphy CJ; Bentley E; Miller PE; McIntyre K; Leatherberry G; Dubielzig R; Giuliano E; Moore CP; Phillips TE; Smith PB; Prescott E; Miller JM; Thomas P; Scagliotti R; Esson D; Gadek T; O'Neill CA
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3174-80. PubMed ID: 21330663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
    Maxwell WA; Reiser HJ; Stewart RH; Cavanagh HD; Walters TR; Sager DP; Meuse PA
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):593-9. PubMed ID: 19040348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
    Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
    Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.
    Mundasad MV; Novack GD; Allgood VE; Evans RM; Gorden JC; Yerxa BR
    J Ocul Pharmacol Ther; 2001 Apr; 17(2):173-9. PubMed ID: 11324984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.
    Malhotra RP; Meier E; Torkildsen G; Gomes PJ; Jasek MC
    Clin Ophthalmol; 2019; 13():403-413. PubMed ID: 30858690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects.
    Jauhonen HM; Kari E; Pylkkänen L; Poutanen J; Laihia J; Kaarniranta K; Leino L
    Acta Ophthalmol; 2015 Jun; 93(4):368-76. PubMed ID: 25611308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma.
    Martin P; Cohen A; Uddin S; Epelbaum L; Josiah S
    Clin Ophthalmol; 2020; 14():885-896. PubMed ID: 32256046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.